Belenos Biosciences and its partner Keymed Biosciences have announced a significant milestone in the development of BEL512, a novel subcutaneous therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). Following a successful Phase II trial in China, the companies are preparing to advance BEL512 into Phase III studies, aiming to carve out a significant share in a market currently dominated by Sanofi and Regeneron’s blockbuster drug, Dupixent.
The positive Phase II readout, which met its primary and secondary endpoints, provides crucial validation for BEL512’s dual-targeting mechanism, inhibiting both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13). This innovative approach aims to address the underlying type 2 inflammation driving CRSwNP, offering a potentially more comprehensive and durable treatment option for patients. The successful trial results have fueled optimism, with Belenos securing ex-China rights to the therapy in a deal valued up to $185 million. The companies are now gearing up for pivotal Phase III trials, with Keymed planning to initiate a study in China and Belenos targeting an ex-China launch in the first half of 2027. This strategic move signals a direct challenge to the established market leadership of Dupixent, a drug that has redefined treatment paradigms for a wide range of type 2 inflammatory diseases.
Main Facts: A Promising Phase II Victory Ignites Phase III Ambitions
Belenos Biosciences and Keymed Biosciences have achieved a critical success with their co-developed drug, BEL512 (also known as CM512 in Greater China), for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The Phase II trial, conducted in China and designated NCT06930612, enrolled 120 patients and demonstrated that BEL512, administered subcutaneously alongside daily nasal corticosteroids, significantly improved key clinical outcomes.
The trial met its primary endpoint by demonstrating a statistically significant reduction in nasal polyp scores from baseline at the 24-week mark. Beyond this crucial primary objective, BEL512 also showed positive results across several secondary endpoints. These included notable improvements in nasal congestion, a reduction in the overall severity of CRSwNP symptoms, and a significant amelioration of smell dysfunction, a debilitating symptom for many CRSwNP patients.
Furthermore, the safety profile of BEL512 in the Phase II study was encouraging. Patients receiving the investigational therapy exhibited a comparable rate of treatment-emergent adverse events (TEAEs) to those in the placebo group, suggesting a favorable tolerability profile. While detailed data is yet to be fully disclosed, Belenos has indicated that comprehensive results will be presented at an upcoming scientific meeting.
These positive findings have propelled Belenos and Keymed towards the next stage of development. The companies have announced their intention to advance BEL512 into Phase III clinical studies. Keymed will spearhead a Phase III trial for CM512 within China, while Belenos is set to initiate an ex-China Phase III study in the first half of 2027. This strategic progression underscores the confidence both organizations have in BEL512’s potential to become a leading treatment option for CRSwNP.
Chronology: A Strategic Partnership Fuels Development
The journey of BEL512 from concept to potential market contender is marked by strategic collaborations and scientific innovation. Keymed Biosciences, the originator of the bispecific antibody, has been instrumental in its early-stage development. The significant partnership with Belenos Biosciences, forged in 2024, marked a pivotal moment, with Belenos acquiring the ex-China rights to BEL512 for an upfront payment of $15 million, with the potential for further milestone payments up to $185 million. This financial commitment highlights Belenos’ strong belief in the therapeutic promise of BEL512.
The successful completion of the Phase II trial in China represents the culmination of earlier research and development efforts. The trial itself, identified by the clinical trial identifier NCT06930612, was designed to evaluate different dosing regimens and schedules of BEL512 in combination with standard-of-care nasal corticosteroids. The enrollment of 120 patients provided a robust dataset for assessing the drug’s efficacy and safety.
Key Milestones:
- 2024: Belenos Biosciences secures ex-China rights to BEL512 from Keymed Biosciences for an upfront payment of $15 million, with potential milestones reaching $185 million.
- [Specific Date of Phase II Topline Readout – assumed to be recent based on article context]: Keymed Biosciences announces topline results from the Phase II trial (NCT06930612) in China, demonstrating significant efficacy and favorable safety.
- [Current Date]: Belenos and Keymed announce their intention to initiate Phase III studies for BEL512/CM512 in CRSwNP. Keymed will commence a Chinese Phase III study, while Belenos targets an ex-China Phase III launch in H1 2027.
This timeline illustrates a focused and accelerated development pathway, driven by a strong scientific rationale and a strategic commercial partnership.
Supporting Data: Unpacking the Science Behind BEL512’s Efficacy
The efficacy of BEL512 in the Phase II trial is rooted in its innovative bispecific antibody design, targeting two key inflammatory mediators: thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13). This dual-targeting approach is designed to provide a more comprehensive blockade of the type 2 inflammatory cascade that underpins CRSwNP and other related conditions.
Mechanism of Action:
- TSLP Inhibition: TSLP is a cytokine released by epithelial cells in response to various stimuli, acting as a master regulator of allergic inflammation. It promotes the differentiation of T helper 2 (Th2) cells and the release of downstream inflammatory mediators. By inhibiting TSLP, BEL512 aims to dampen the initial inflammatory signals that drive CRSwNP.
- IL-13 Inhibition: IL-13 is a key cytokine produced by Th2 cells, playing a critical role in various aspects of type 2 inflammation, including airway hyperresponsiveness, mucus production, and eosinophilic inflammation. It is a major driver of polyp formation and nasal congestion in CRSwNP. By neutralizing IL-13, BEL512 directly targets downstream inflammatory processes.
The combination of inhibiting both up- and downstream drivers of inflammation is theorized to offer synergistic benefits, leading to a more profound and durable control of disease activity.
Phase II Trial Results (Week 24):
- Primary Endpoint: Significant change in patient nasal polyp scores from baseline. This objective measure of disease severity is a critical indicator of treatment effectiveness in CRSwNP.
- Secondary Endpoints:
- Improvements in nasal congestion: Addressing a primary symptom that significantly impacts patient quality of life.
- Reduction in total symptoms of CRSwNP: A comprehensive assessment of the disease burden.
- Alleviation of loss of smell: Restoring a crucial sensory function often impaired in CRSwNP patients.
- Safety and Tolerability: Treatment-emergent adverse events (TEAEs) were comparable between BEL512 and placebo groups, suggesting a favorable safety profile.
The infrequent dosing regimen, as hinted at by CEO Donnie McGrath, is another significant potential advantage of BEL512, which could further enhance patient compliance and convenience compared to more frequent administration schedules.
Official Responses: Confidence and Vision for the Future
The successful Phase II results have elicited strong expressions of confidence from the leadership of both Belenos Biosciences and Keymed Biosciences. The positive outcomes are seen as a crucial validation of their therapeutic strategy and a significant step towards addressing an unmet medical need in CRSwNP.
Donnie McGrath, CEO of Belenos Biosciences, emphasized the significance of the Phase II findings:
"The Phase II findings provide important clinical validation for targeting TSLP and IL-13 in tandem for CRSwNP treatment. The magnitude, speed of onset and durability of improvement across objective measures of nasal polyp disease and the symptoms that matter most to patients, in conjunction with infrequent dosing indicate that BEL512 may offer patients an attractive treatment option."
McGrath further articulated the broader implications of this success:
"These findings further strengthen our conviction in BEL512 as a potentially best-in-class therapy across multiple respiratory and inflammatory diseases."
This statement highlights Belenos’ ambition to position BEL512 not just as a CRSwNP treatment, but as a versatile therapeutic agent with potential applications in a range of other type 2 inflammatory conditions.
While Keymed Biosciences’ direct quotes on this specific readout were not detailed in the provided text, their commitment to initiating a Phase III study in China underscores their belief in the drug’s potential. The co-development and licensing agreement itself, with its substantial upfront and potential milestone payments, is a strong testament to Keymed’s confidence in BEL512’s clinical and commercial prospects.
The companies’ collective pronouncements paint a picture of unwavering determination to bring BEL512 to patients, with a clear roadmap for the critical Phase III development stages.
Implications: Challenging Dupixent’s Reign in a Crowded Market
The successful progression of BEL512 into Phase III trials carries significant implications for the CRSwNP treatment landscape, which has been largely defined by the success of Dupixent (dupilumab) since its approval in 2019. Dupixent, a monoclonal antibody targeting the IL-4 receptor alpha subunit, has achieved blockbuster status, generating billions in global sales and securing numerous indications across various type 2 inflammatory diseases. In 2025 alone, Dupixent is projected to have generated $17.8 billion in global sales, underscoring its profound impact on patient care and the pharmaceutical market.
Key Implications:
- Market Disruption Potential: BEL512’s dual-targeting mechanism and promising Phase II results suggest it could offer a differentiated therapeutic profile compared to Dupixent. If BEL512 demonstrates comparable or superior efficacy, particularly in terms of durability and symptom relief, it could indeed challenge Dupixent’s dominance in CRSwNP and potentially other type 2 inflammatory conditions.
- Competition and Innovation: The pursuit of new targets and long-acting therapies like BEL512 by companies like Belenos and others signifies a dynamic and competitive environment. This innovation is crucial for advancing patient care and providing alternative treatment options, especially for those who may not respond optimally to existing therapies or seek different administration profiles.
- Broader Therapeutic Applications: Similar to Dupixent’s extensive approval history, BEL512 is also being explored for other conditions, including asthma, chronic spontaneous urticaria (CSU), eczema, and chronic obstructive pulmonary disease (COPD). A successful track record in CRSwNP could pave the way for broader indications and a more comprehensive market presence for BEL512.
- Patient Choice and Access: The introduction of a new, potentially highly effective therapy like BEL512 would expand treatment options for CRSwNP patients. This increased competition could lead to greater patient access, potentially driving down costs and improving the overall standard of care.
- Strategic Landscape: The move into Phase III signifies a critical juncture for Belenos and Keymed. Successful Phase III trials will be essential for securing regulatory approvals and establishing a strong market position. The race to gain market share will likely involve significant commercialization efforts, including robust marketing campaigns and strategic partnerships.
While the journey ahead for BEL512 is still marked by the rigorous demands of Phase III clinical trials and regulatory scrutiny, the positive Phase II outcomes have undeniably positioned it as a formidable contender. The coming years will be crucial in determining whether BEL512 can indeed carve out a significant niche and potentially reshape the treatment paradigm for CRSwNP, offering a new beacon of hope for patients battling this chronic and debilitating condition.
About the Author
